Current surgical management of chronic thromboembolic pulmonary disease.
cardiothoracics
pulmonary embolism
pulmonary hypertension
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
12
04
2024
accepted:
04
06
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
Chronic thromboembolic pulmonary disease (CTEPD) with or without pulmonary hypertension (PH) is an important potential consequence of venous thromboembolic disease. Untreated CTEPD with pulmonary hypertension (CTEPH) is associated with high rates of morbidity and mortality. Several treatment options are now available for patients with CTEPD and CTEPH, including pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, medical therapy or a combination of therapies. Choice of treatment depends on the location of the thromboembolic disease burden, presence and severity of PH and patient factors, including frailty, parenchymal lung disease and other comorbidities. PEA is a complex surgery that can result in excellent outcomes and resolution of disease, but also comes with the risk of serious perioperative complications. This manuscript examines the history of PEA and its place in Australasia, and reports on outcomes from the main Australasian CTEPH expert centre. It provides a summary of up-to-date guidance on how PEA should be utilised in the overall management of these patients and describes opportunities and challenges for the future diagnosis and management of this disease, particularly in the Australasian setting.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731.
Luijten D, Talerico R, Barco S, Cannegieter SC, Delcroix M, Ende‐Verhaar YM et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta‐analysis. Eur Respir J 2023; 62: 2300449.
Ende‐Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017; 49: 1601792.
Simonneau G, Torbicki A, Dorfmuller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26: 160112.
Jamieson S, Pomar J. Surgical treatment for chronic thromboembolic pulmonary hypertension: an historical perspective. Ann Cardiothorac Surg 2022; 11: 98–105.
Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow‐up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: 151–158.
Lewczuk J, Piszko P, Jagas J, Porada A, Wojciak S, Sobkowicz B et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001; 119: 818–823.
Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev 2017; 26: 160121.
Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L et al. Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 2010; 8: 1248–1255.
Alonso‐Martínez JL, Anniccherico‐Sánchez FJ, Urbieta‐Echezarreta MA, García‐Sanchotena JL, Herrero HG. Residual pulmonary thromboemboli after acute pulmonary embolism. Eur J Intern Med 2012; 23: 379–383.
Cosmi B, Nijkeuter M, Valentino M, Huisman MV, Barozzi L, Palareti G. Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med 2011; 6: 521–528.
Pugliese SC, Kawut SM. The post‐pulmonary embolism syndrome: real or ruse? Ann Am Thorac Soc 2019; 16: 811–814.
Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915.
Guth S, Mayer E, Prüfer D, Wiedenroth CB. Pulmonary endarterectomy: technique and pitfalls. Ann Cardiothorac Surg 2022; 11: 180–188.
Bergquist CS, Wu X, McLaughlin VV, Rosati CM, Pretorius V, Likosky DS et al. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: an STS database analysis. Ann Thorac Surg 2022; 114: 2157–2162.
Brookes JDL, Li C, Chung STW, Brookes EM, Williams ML, McNamara N et al. Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review. Ann Cardiothorac Surg 2022; 11: 68–81.
Madani MM. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: state‐of‐the‐art 2020. Pulm Circ 2021; 11: 20458940211007372.
Jenkins D, Madani M, Fadel E, D'Armini AM, Mayer E. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26: 160111.
Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702–710.
Lankeit M, Krieg V, Hobohm L, Kolmel S, Liebetrau C, Konstantinides S et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017; 37: 250–258.
Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26: 160119.
Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E et al. Dynamic risk stratification of patient long‐term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort. Circulation 2016; 133: 1761–1771.
Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–329.
Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T et al. Long‐term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922–927.
Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134: 229–236.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jais X et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT‐1): results from the multicentre, phase 2, randomised, double‐blind, placebo‐controlled study. Lancet Respir Med 2024; 12: e21–e30.
Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo‐controlled trial. J Am Coll Cardiol 2008; 52: 2127–2134.
Maliyasena VA, Hopkins PM, Thomson BM, Dunning J, Wall DA, Ng BJ et al. An Australian tertiary referral center experience of the management of chronic thromboembolic pulmonary hypertension. Pulm Circ 2012; 2: 359–364.
Bart NK, Ambati C, Kearney K, Scheuer S, Emmanuel S, Wilson M et al. Outcomes of patients with chronic thromboembolic pulmonary hypertension risk stratified by a dedicated heart team to receive pulmonary endarectomy or balloon pulmonary angiogiplasty. J Heart Lung Transplant 2020; 39: S170.
Liu J, Yang P, Tian H, Zhen K, McCabe C, Zhao L et al. Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. J Transl Int Med 2022; 10: 125–133.
Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020; 18: 114–122.
Delcroix M, Lang I, Pepke‐Zaba J, Jansa P, D'Armini AM, Snijder R et al. Long‐term outcome of patients with chronic thromboembolic pulmonary hypertension. Circulation 2016; 133: 859–871.
Quadery SR, Swift AJ, Billings CG, Thompson AAR, Elliot CA, Hurdman J et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52: 1800589.
Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57: 2002828.
Pepke‐Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973–1981.
Hsieh WC, Jansa P, Huang WC, Niznansky M, Omara M, Lindner J. Residual pulmonary hypertension after pulmonary endarterectomy: a meta‐analysis. J Thorac Cardiovasc Surg 2018; 156: 1275–1287.